MediWound (MDWD) announced it has entered into a research collaboration agreement with MiMedx (MDXG). MiMedx will provide its market placental tissue allograft Epifix to be used during the wound healing phase of the EscharEx Phase III study in venous leg ulcers, or VLUs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDWD:
- MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
- MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
- MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
- Mediwound (MDWD) Q2 Earnings Cheat Sheet
- Three new option listings and two option delistings on August 4th